EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

First Onset of Pityriasis Rubra Pilaris following SARS-CoV-2 Booster Vaccination: Case Report and Review of the Literature

Thilo Gambichler, Christina H. Scheel, Yousef Arafat, Ekaterina Heinzer, Kathrin Noldes, Zenaida Bulic, Stefanie Boms

Dermato · 2022

DOI: 10.3390/dermato2030008 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Dermato, 2022. Verfasst von Thilo Gambichler und 6 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is increasing evidence of adverse events associated with the use of COVID-19 vaccines. Here, we report a case of the SARS-CoV-2-vaccination-related onset of pityriasis rubra pilaris (PRP) and provide an analysis of previously reported cases in the medical literature. A 67-year-old male presented with a 1-year history of histopathologically proven PRP that first developed 14 days after receiving a COVID-19 booster vaccination. Skin symptoms improved under ustekinumab medication after unsuccessful previous treatment approaches using systemic corticosteroids, brodalumab, and risankizumab. Among the published cases of post-COVID vaccination PRP, 12 (75%) males and 4 (25%) females were reported. The median age of the reported patients was 59 years. In 10 out of 16 patients (62.5%), PRP was diagnosed after the first vaccine dose, in 4 (25%) after the second dose, and in 2 of 15 patients (12.5%) after the third dose. The median time between COVID-19 vaccination and the onset of PRP was 9.5 days (range: 3–60 days). The majority of patients required systemic treatment, including systemic retinoids and methotrexate. PRP might be a rare adverse event after COVID-19 vaccination, particularly affecting older males. Even though most reported patients with COVID-19-vaccination-related PRP could be successfully treated with PRP standard medications, therapy refractory cases may also occur. Thus, clinicians must be aware of this rare but potentially severe complication.

Zitieren

APA

Gambichler, T., Scheel, C. H., Arafat, Y., Heinzer, E., Noldes, K., Bulic, Z., & Boms, S. (2022). First Onset of Pityriasis Rubra Pilaris following SARS-CoV-2 Booster Vaccination: Case Report and Review of the Literature. Dermato. https://doi.org/10.3390/dermato2030008

Vancouver

Gambichler T, Scheel CH, Arafat Y, Heinzer E, Noldes K, Bulic Z, et al. First Onset of Pityriasis Rubra Pilaris following SARS-CoV-2 Booster Vaccination: Case Report and Review of the Literature. Dermato. 2022. doi:10.3390/dermato2030008

BibTeX
@article{Gambichler2022,
  author = {Gambichler, Thilo and Scheel, Christina H. and Arafat, Yousef and Heinzer, Ekaterina and Noldes, Kathrin and Bulic, Zenaida and Boms, Stefanie},
  title = {First Onset of Pityriasis Rubra Pilaris following SARS-CoV-2 Booster Vaccination: Case Report and Review of the Literature},
  journal = {Dermato},
  year = {2022},
  doi = {10.3390/dermato2030008}
}
Kostenlos starten →